SVB Securities analyst Andrew Berens maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of $75.00. The company's shares closed last Tuesday at $67.17. According to TipRanks.com, Berens is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.1% and a 38.9% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Global Blood Therapeutics. Currently, the analyst consensus on AstraZeneca is a Moderate Buy with an average price target of $75.00. See today’s best-performing stocks on TipRanks >> The company has a one-year high of $71.
https://www.tipranks.com/news/blurbs/astrazeneca-azn-receives-a-buy-from-svb-securities?utm_source=advfn.com&utm_medium=referral
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Mai 2022 bis Jun 2022 Click Here for more AstraZeneca Charts.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Jun 2021 bis Jun 2022 Click Here for more AstraZeneca Charts.